トランプ氏も使った抗体カクテル薬

 抗体カクテル薬、在宅患者にも投与　首相が表明

重症者拡大に備え、軽症らは自宅療養に

菅義偉首相は2日夕、首相官邸で開いた新型コロナウイルスの医療提供体制に関する関係閣僚会議で、軽症・中等症患者向けの治療薬「抗体カクテル療法」を入院患者以外も使用できるようにする方針を表明した。「在宅患者も含めた取り組みを進める」と述べた。

重症者や重症化リスクがある人が確実に入院できる体制を整えるため、軽症者らは自宅療養を基本とするとも強調した。

重症化予防が期待される「抗体カクテル療法」は現在、入院患者しか使用できず外来診療の対象になっていない。首相は「50代以上や基礎疾患のある人に積極的に投与する」と話した。

自宅療養の環境整備に向け、往診やオンライン診療を充実させる考えを示した。往診の診療報酬を引き上げると説明した。

2021年8月2日 18:25
日経新聞https://www.nikkei.com/article/DGXZQODE0274O0S1A800C2000000/

トランプ氏も使った抗体カクテル療法、月内にも承認へ [新型 ...

https://www.asahi.com › articles

2021/07/12 — 新型コロナウイルスの治療薬候補の「抗体カクテル療法」について、厚生労働省は近く部会を開いて製造販売について審議し、月内にも承認する方向で最終 ...

トランプ氏に投与も・・・治療薬“抗体カクテル”承認へ(2021 ...

https://www.youtube.com › watch

2021/07/12 — 厚生労働省は、新型コロナウイルスの軽症用などの治療薬として、「抗体カクテル療法」を今月中にも承認する方針です。□米国でトランプ前大統領にも ...

トランプ氏に投与も…治療薬“抗体カクテル”承認へ｜テレ朝 ...

https://news.tv-asahi.co.jp › 社会 › 医療・健康

2021/07/13 — 厚生労働省は、新型コロナウイルスの軽症用などの治療薬として、「抗体カクテル療法」を今月中にも承認する方針です。 □米国でトランプ前大統領にも ...

（コラム）トランプ氏に投与された新型コロナウィルス治療薬 ...

https://www.boston.us.emb-japan.go.jp › itpr_ja

2020/11/09 — ¹そこでトランプ氏の治療として、抗体カクテル療法とレムデシベルの5日間コースが採用された。¹ 抗体カクテル療法の治療薬「REGN-COV2」とは、新型 ...

トランプ前米大統領に投与された抗体医薬品を国内承認申請 ...

https://news.yahoo.co.jp › articles

2021/07/02 — 抗体カクテル療法を新たな治療薬として一日も早く届けられるよう規制当局と緊密に協働していく」とコメントした。 トランプ前米大統領に投与された抗体 ...

[20210720更新] トランプ大統領に処方されたリジェネロン社 ...

https://crisp-bio.blog.jp › archives

2021/07/20 — https://www.chugai-pharm.co.jp/news/detail/20210719220000_1129.html; 日本経済新聞 「第4のコロナ薬，抗体カクテル療法承認 重症化抑制期待」2021-07- ...

情報BOX：抗体カクテルを使用、トランプ氏のコロナ治療 ...

https://jp.reuters.com › article › health-coronavirus-tru...

2020/10/03 — ビタミンD・亜鉛：免疫システムにとって重要な要素で免疫力アップを目的に摂取する人もいる。 ファモチジン：胸やけの薬。新型コロナウイルス感染症への ...

Trump’s Covid-19 antibody treatment was partly developed using Singaporean blood plasma

• One of the two antibodies used in an experimental treatment for the US President was developed using blood samples from three patients in Singapore
• The city state has been recruiting patients who have recovered from the coronavirus to donate blood

Published: 9:24pm, 6 Oct, 2020

Updated: 1:13pm, 7 Oct, 2020

One of the two antibodies used in an experimental treatment for US President Donald Trump was developed using blood samples from three patients in Singapore , according to a report by Asian Scientist Magazine published on Monday.

The science and technology publication noted that Trump had on Friday received a “high dose” of an experimental antibody therapy known as REGN-COV2 developed by American biotechnology company Regeneron.

The treatment – a combination of two antibodies against the coronavirus spike protein – had shown promising results in an earlier trial involving 275 patients. In those cases, patients reported reduced viral levels and improved symptoms, the report said.

Trump received the antibody cocktail before he was admitted to the Walter Reed National Military Medical Center, and while he was there for three days, he was also given multiple doses of the antiviral drug, Remdesivir and a steroid dexamethasone, usually used to treat inflammation in people who have severe cases of Covid-19.

Trump was discharged from hospital on Monday evening and in a video released shortly after he was ensconced in the White House said he was feeling better.

Dr Jonathan Reiner, a professor of medicine at George Washington University, told CNN:

“The president might be the only patient on the planet ever to receive this particular combination of medicines.”

Indeed, REGN-COV2 has not received emergency use authorisation from the US Food and Drug Administration and the biotech firm said it had provided the drug in response to Trump’s doctors making a “compassionate use” request.

Asian Scientist Magazine said convalescent plasma from patients who had recovered from Covid-19 could be used to prevent or treat the disease but even with the US Food and Drug Administration authorising the emergency use of convalescent plasma, the difficulty of obtaining sufficient blood from volunteers meant it was not possible to use it at a large scale.

Instead, the Regeneron therapy clones antibodies from both “humanised” mice and recovered patients to produce a reliable source of monoclonal antibodies, reported the magazine.

“While the humanised mice were based on a technology owned by Regeneron, the human plasma used was supplied through an agreement with Singapore’s National Centre for Infectious Diseases,” it added.

Reports of antibody treatments in the works emerged in June, with most of them in labs across Asia, including Singapore, Japan, China and South Korea. Scientists explained that the treatment works by harvesting specific antibodies – produced by the body to fight off diseases when an individual catches a virus – to trigger other parts of the immune system to attack the cells containing the toxin.

For Singapore, its defence research and development organisation DSO National Laboratories had announced in June that it had discovered five antibodies that could block the coronavirus and protect against key mutations, after scientists screened hundreds of thousands of cells that produce the antibodies.

The country’s government-linked biomedical sciences institute A*Star is working with Japanese pharmaceutical company Chugai Group separately on similar treatments.

Local media has also reported that the Singapore authorities have also been recruiting patients who have recovered from the coronavirus to donate blood for such purposes.

When news that Trump had received the treatment broke, some experts were concerned at why emergency use had been authorised even though the trials had not finished. Dr Jeremy Faust, a public health expert at Harvard, said it raised uncomfortable possibilities: either the president’s team had not understood the scientific process, or they had understood but were overridden by Trump on someone else’s advice.

“People will see this and they’ll think that this is the treatment you should have – and if you don’t give it to other people who have coronavirus that we’re denying them special treatment.

“In reality that’s not the case … we shouldn’t be treating the president as a guinea pig,” he told Agence France-Presse.

While Regeneron has not released detailed data from its clinical trial of 275 patients, it said it had seen “infusion reactions” in four patients, two on placebo and two on the drug, while “serious adverse events” occurred in two placebo patients and one on the drug. No one died.

The company did not detail what these side effects were, but Dr Arun Swaminath, a doctor at New York’s Lenox Hill Hospital, said that in general, mild reactions to IV-therapies include fevers, chills and fatigue. More serious symptoms include chest pain and shortness of breath.

Regeneron has moved to late-stage outpatient trials, including for hospitalised Covid-19 patients in

Britain

and for the drug’s potential use to prevent household contacts of Covid-19 patients from being infected.

https://www.scmp.com/week-asia/health-environment/article/3104427/trumps-covid-19-antibody-treatment-was-partly

 

2021年8月2日月曜日

将来、多くの命を救うのは健康なワクチン未接種者

将来たぶん未接種者からの抗体以外に切羽詰まったワクチン未接種の重症患者の命を救う術がなくなる。

ワクチン接種者の命は救えない。 

子供や若者にワクチンを打ちまくった国は滅ぶ。

大丈夫アルカ？宗主国様？（爆ｗｗｗｗｗｗｗｗｗｗｗｗ

https://tokumei10.blogspot.com/2021/08/blog-post_44.html

しかし・・・

 もうダメですな。（爆ｗｗｗｗｗｗｗｗｗｗｗ

で、そんなもんあかんとほざいてるのが・・・

　prognosis

Trump-Touted Plasma Therapy Shows No Benefit, Researchers Say

January 15, 2021, 8:26 AM HST

A large, national study in the U.K. examining convalescent plasma as a therapy for Covid-19 was ended after a finding that the treatment touted by U.S. President Donald Trump doesn’t work.

The University of Oxford research was part of a clinical trial named Recovery that’s investigating different Covid-19 treatments. The only arm of the study stopped was one probing the effectiveness of a therapy using plasma from people who have recovered from the virus. A monitoring board said on Thursday there was no point in continuing, the university said in a statement.

The decision comes after more than 100,000 Americans have been treated with convalescent plasma after its use was authorized by U.S. regulators on an emergency basis. Trump commented at the time in August that it would “save countless lives.”

“Convalescent plasma has been widely used as a treatment for Covid-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with Covid-19,” according to the statement.

The U.S. National Institutes of Health is leading ongoing convalescent plasma research in the U.S., but expectations are modest at best as well.

Trump and U.S. Food and Drug Administration Commissioner Stephen Hahn held a press conference in August announcing the FDA would authorize use of convalescent plasma on an emergency basis against Covid-19, though evidence of its effectiveness was thin. Trump strongly touted the therapy, while Hahn exaggerated its benefit in remarks he had to walk back shortly after.

Peter Horby, one of the lead researchers on Recovery, said it is still possible some subgroups of patients could benefit from convalescent plasma.

“Whilst the overall result is negative, we need to await the full results before we can understand whether convalescent plasma has any role in particular patient subgroups.,” Horby, professor of emerging infectious diseases in the Nuffield Department of Medicine at the University of Oxford, said in the statement.

https://www.bloomberg.com/news/articles/2021-01-15/trump-touted-plasma-therapy-shows-no-benefit-researchers-say

オックスフォード@ナチス - 匿名党

http://tokumei10.blogspot.com › 2021/07 › blog-post_64

2021/07/22 — Romocea said: "It's thought Hitler was never intent on bombing Oxford because he wanted to make it the new capital of his new kingdom.

Oxford: Hitler's Choice | Cherwell

https://cherwell.org › News

2007/09/30 — Oxford: Hitler's Choice ... Oxford was to be the capital of Hitler's new kingdom, according to invasion plans unearthed at the Bodleian Library, ...

Hitler's Oxford plans revealed | Oxford Mail

https://www.oxfordmail.co.uk › news

2007/09/26 — Hitler wasn't kidding when he threatened to invade Britain - and ... because he wanted to make it the new capital of his new kingdom.

Seven Things You Didn't Know About Oxford – The Oxford ...

https://www.oxfordstudent.com › sev...

2012/09/15 — ... to Hitler's plan to invade the United Kingdom, suggesting that the Nazi leader intended to make Oxford the capital of his new kingdom.

、、、（爆ｗｗｗｗｗｗｗｗｗｗｗｗｗ